Skip Navigation



Glycobiology Advance Access published online on January 18, 2008
Glycobiology, doi:10.1093/glycob/cwm137
This Article
Right arrow Advance Access manuscript (PDF)
Right arrow All Versions of this Article:
18/3/235    most recent
cwm137v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Jin, C.
Right arrow Articles by Steinkellner, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jin, C.
Right arrow Articles by Steinkellner, H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oxfordjournals.org

A plant derived human monoclonal antibody induces an anti-carbohydrate immune response in rabbits

Chunsheng Jin2, Friedrich Altmann2, Richard Strasser1, Lukas Mach1, Matthias Schähs1, Renate Kunert3, Thomas Rademacher4, Josef Glössl1 and Herta Steinkellner1,*

1 Institute of Applied Genetics and Cell Biology
2 Department of Chemistry
3 Institute of Applied Microbiology, University of Natural Resources and Applied Life Sciences, Muthgasse 18, 1190 Vienna, Austria
4 Rheinisch-Westfälische Technische Hochschule, Worringerweg 1, 52074, Aachen, Germany

* Corresponding Author: Tel: +43-1-36006-6700, Fax: +43-1-36006-6392, e-mail: herta.steinkellner{at}boku.ac.at

Received on July 26, 2007; accepted on December 21, 2007

A common argument against using plants as a production system for therapeutic proteins is their inability to perform authentic N-glycosylation. A major concern is the presence of beta 1,2-xylose and core alpha 1,3-fucose residues on complex N-glycans as these non-mammalian N-glycan residues may provoke unwanted side effects in humans. In this study we have investigated the potential antigenicity of plant-type N-glycans attached to a human monoclonal antibody (2G12). Using glyco-engineered plant lines as expression hosts, four 2G12 glycoforms differing in the presence/absence of beta 1,2-xylose and core alpha 1,3-fucose were generated. Systemic immunisation of rabbits with a xylose and fucose carrying 2G12 glycoform resulted in a humoral immune response to both N-glycan epitopes. Furthermore, IgE immunoblotting with sera derived from allergic patients revealed binding to plant-produced 2G12 carrying core alpha 1,3 fucosylated N-glycan structures. Our results provide evidence for the adverse potential of non-mammalian N-glycan modifications present on monoclonal antibodies produced in plants. This emphasizes the need for the use of glyco-engineered plants lacking any potentially antigenic N-glycan structures for the production of plant derived recombinant proteins intended for parenteral human application.

Key words: plants / recombinant antibodies / N-glycosylation / beta1,2 xylose / core alpha 1,3 fucose / glyoengineering / anti-carbohydrate immune response


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.